论文部分内容阅读
英国SK—F实验室研制的组织胺H_2受体拮抗剂甲腈咪胍(Cimetidine),于1976年投放英国市场,到1978年底,包括美国在内的90多个国家开始临床应用,迄今国内外已广泛采用。临床实践证明,甲腈咪胍能显著地抑制胃酸分泌,预防实验动物和危重病人的应激性溃疡和出血,减少溃疡的复发率和手术率,用于治疗消化性溃疡、Zollinger—Ellison综合征和上消化道出血确实有效。随着甲腈咪胍在临床的广泛应用,有关副作用的报告也渐增多,本文仅就其肾脏毒性综述如下。
Cimetidine, a histamine H 2 receptor antagonist developed by British SK-F laboratory, was put on the UK market in 1976. By the end of 1978, more than 90 countries, including the United States, had started clinical application. Up to now, Has been widely used. Clinical practice has proved that nitidomycin can significantly inhibit gastric acid secretion, prevention of experimental animals and critically ill patients with stress ulcers and bleeding, reduce the recurrence rate of ulcers and surgical rates for the treatment of peptic ulcer, Zollinger-Ellison syndrome And upper gastrointestinal bleeding really effective. With the extensive use of cetylidine in clinical practice, reports of side effects have also been increasing. This article reviews the renal toxicity only as follows.